Biomarker Testing, Incorporation of New Drug Approvals Among New Guidance in Updated Living Guideline on Stage IV NSCLC With Driver Alterations

ASCO has published a full update to its living guideline on the treatment of patients with stage IV NSCLC with driver alterations. The update incorporates recent evidence and drug approvals across treatment lines and driver alterations—including EGFR mutations, acquired MET amplification, ROS1 rearrangements, and HER2 exon 20 mutations—and emphasizes comprehensive molecular profiling plus immunohistochemistry testing to guide treatment decision-making.